BCC Research
BCC Research

Viatris Inc.

Company Snapshot

Founded: 2020
Entity Type: Public
Employees: 32,000
Region: North America and Europe
Revenue: $14,692.8 Millions
Revenue Year: 2024
Headquarter: Pennsylvania, U.S.
Key Geographics: North America, Europe, Asia-Pacific, Rest of the World

Company Overview

Viatris Inc., headquartered in Pittsburgh, Pennsylvania, is a global pharmaceutical company formed in November 2020 by merging Mylan N.V. and Pfizer Inc.’s Upjohn division. The company focuses on providing access to affordable, high-quality medicines worldwide, operating in numerous countries with a diverse portfolio of generic drugs and biosimilars. Viatris Inc. is committed to improving global healthcare access and empowering individuals to lead healthier lives.

The executive team leads the company’s efforts, and it invests in R&D to advance its product pipeline. Viatris Inc. engages in various corporate social responsibility initiatives as a pharmaceutical entity, including sustainability and community engagement. Not all the products listed have been approved for use in all countries.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Viatris Inc. In Reports

Global Markets for Allergy Diagnostics and Treatments

BCC Research Market Report for allergy diagnostic and treatment market trends of allergy diagnostics and treatments with data from 2023, estimates from 2024, projections of CAGR through 2029 (forecast period 2024...

Needle-Free Devices: Technologies and Global Markets

Our Research report provides an overview of the global needle free devices technologies and market and analyzes market trends includes global revenue ($ Million) for base year data for 2024 and estimated data for the...

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

BCC Research Report: Dive into pharmaceutical drugs market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

View All Reports

Viatris Inc. In News

J&J’s Invega Sustenna Patent Survives Teva, Viatris Appeals - Bloomberg Law News

Bloomberg Law News - Jul 08, 2025

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook - Viatris

Viatris - May 08, 2025

Fda discontinues Mylan Pharmaceuticals' potassium chloride tablet - MarketScreener

MarketScreener - Jul 08, 2025

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia - PR Newswire

PR Newswire - Jun 26, 2025

Read All News

Company's Business Segments

  • Brands : Lipitor, Norvasc, Caduet, Inspra, Nitrostat, Revatio, Dilatin, Lyrica, Neurontin, Relpax
  • Generics : Wixela, Inhub, ADVAIR DISKUS, Glatiramer acetate injection, Copaxone

Applications/End User Industries

  • Governments
  • Healthcare Providers
  • Consumer
  • Pharmaceuticals
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

Contact

© 2025 BCC Research

Privacy Policy |Site Map|Terms & Conditions